Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from AstraZeneca ( (GB:AZN) ) is now available.
AstraZeneca announced that its CEO, Pascal Soriot, has gifted 136,537 ordinary shares of the company to family members without any financial consideration. This transaction was conducted outside a trading venue and aligns with the regulatory requirements of the EU Market Abuse Regulation, reflecting transparency in executive shareholding activities.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call are the primary drivers of its stock score. The company’s robust revenue growth, high profitability, and strategic progress in key markets are significant strengths. However, the high valuation and some cash flow management challenges slightly temper the overall score.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK. It focuses on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca’s innovative medicines are available in over 125 countries and serve millions of patients worldwide.
Average Trading Volume: 2,074,906
Technical Sentiment Signal: Buy
Current Market Cap: £200B
For a thorough assessment of AZN stock, go to TipRanks’ Stock Analysis page.